Regen Biopharma Inc. (RGBPP) 0.1875 $RGBPP Rege
Post# of 273242
Posted On: 09/19/2016 11:07:03 PM
Regen Biopharma Inc. (RGBPP) 0.1875 $RGBPP
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
PR Newswire - Wed Sep 14, 7:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
PR Newswire - Thu Aug 25, 7:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
PR Newswire - Tue Aug 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented new interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. Pan Am Cancer Treatment Center has now provided 3 month follow up data in these same patients. The primary endpoint of the study is safety and the secondary endpoint is effectiveness.
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
PR Newswire - Thu Jun 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
PR Newswire - Tue Jun 07, 6:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen's NR2F6 tCellVax and small molecule programs.
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
PR Newswire - Thu Jun 02, 6:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a "checkpoint inhibitor pill." Previously, the Company reported the use of gene silencing of NR2F6 leads to:
Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
PR Newswire - Wed Jun 01, 8:23AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has been approved by OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace with an effective trading date of May 31, 2016. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
PR Newswire - Tue May 24, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) has applied to OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
PR Newswire - Wed May 11, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) announced today that potential market expansion of its HemaXellerate therapy for aplastic anemia is a strategic priority.
Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
PR Newswire - Thu Apr 21, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
Regen BioPharma, Inc. Responds to FDA on dCellVax Gene-Silenced Breast Cancer Immunotherapy
PR Newswire - Wed Sep 14, 7:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today submission to the Food and Drug Administration (FDA) of a revised Investigational New Drug (IND) application focused on using a novel method to unleash the body's innate ability to kill cancer. The package submitted contained preclinical experiments as well as details of the proposed clinical trial. Results of the studies clearly demonstrated that the approach outlined, using siRNA to silence a key enzyme related to inhibition of the immune system, is effective at stimulating the type of immune response associated with known checkpoint inhibitors.
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
PR Newswire - Thu Aug 25, 7:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.
Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
PR Newswire - Tue Aug 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented new interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. Pan Am Cancer Treatment Center has now provided 3 month follow up data in these same patients. The primary endpoint of the study is safety and the secondary endpoint is effectiveness.
Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
PR Newswire - Thu Jun 16, 7:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP and OTCQB: RGBPP) recently announced that it has identified small molecules that activate the Company's newly identified immune checkpoint, NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties.
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
PR Newswire - Tue Jun 07, 6:00AM CDT
Regen BioPharma, Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding. The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen's NR2F6 tCellVax and small molecule programs.
Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
PR Newswire - Thu Jun 02, 6:00AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) discussed recent initiation of a major effort to identify small molecules that bind to the Company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the Company plans to use as a basis for creating a "checkpoint inhibitor pill." Previously, the Company reported the use of gene silencing of NR2F6 leads to:
Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
PR Newswire - Wed Jun 01, 8:23AM CDT
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) has been approved by OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace with an effective trading date of May 31, 2016. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
PR Newswire - Tue May 24, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) has applied to OTC Markets Group Inc. to uplist Regen's Common and Series A Preferred shares to the OTCQB Venture Marketplace. To be eligible to trade over the OTCQB, companies must be current in their reporting and undergo an annual verification and management certification process.
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
PR Newswire - Wed May 11, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP), (OTCPINK: RGBP) and (OTCPINK: RGBPP) announced today that potential market expansion of its HemaXellerate therapy for aplastic anemia is a strategic priority.
Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
PR Newswire - Thu Apr 21, 6:00AM CDT
Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today that the company's Series A Preferred Stock began trading on the OTC PINK market (PINK: RGBPP). Regen BioPharma's shareholders now have a symbol and a market for the Series A Preferred shares they own.
(0)
(0)Scroll down for more posts ▼